PHATPhathom Pharmaceuticals, Inc.

Nasdaq phathompharma.com


$ 10.62 $ 0.14 (1.34 %)    

Monday, 20-May-2024 12:35:20 EDT
QQQ $ 454.92 $ 2.41 (0.53 %)
DIA $ 399.87 $ -0.01 (-0 %)
SPY $ 531.00 $ 1.45 (0.27 %)
TLT $ 91.14 $ 0.08 (0.09 %)
GLD $ 224.60 $ 1.24 (0.56 %)
$ 10.54
$ 10.48
$ 10.64 x 200
$ 10.69 x 200
$ 10.32 - $ 10.62
$ 6.07 - $ 17.02
533,976
na
615.24M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-07-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-02-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-11-2021 03-31-2021 10-Q
14 03-30-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-19-2020 12-31-2019 10-K
19 11-25-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 phathom-pharmaceuticals-will-present-voquezna-data-at-ddw-2024-annual-meeting-being-held-may-18-21

First oral presentation of Phase 3 data evaluating the investigational use of VOQUEZNA® in Non-Erosive Reflux Disease (NERD)1 N...

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 hc-wainwright--co-reiterates-buy-on-phathom-pharmaceuticals-maintains-28-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $...

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 phathom-pharmaceuticals-q1-2024-gaap-eps-142-misses-128-estimate-sales-1912m-miss-2047m-estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(1.42) per share which missed the analyst consensus estimat...

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 stifel-initiates-coverage-on-phathom-pharmaceuticals-with-buy-rating-announces-price-target-of-24

Stifel analyst Annabel Samimy initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy rating and announces Pr...

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-maintains-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 needham-reiterates-buy-on-phathom-pharmaceuticals-maintains-26-price-target

Needham analyst Joseph Stringer reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.

 hc-wainwright--co-reiterates-buy-on-phathom-pharmaceuticals-maintains-28-price-target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION